UTD1 Combined With Capecitabine in Metastatic HER2-negative Breast Cancer Patients With Brain Metastases

This study is a single-arm, multicenter, open-labeled clinical study of UTD1 combined with Capecitabine in metastatic HER2-negative breast cancaner patients with brain metastases. This study aims to evaluate the efficacy and safety of UDT1 combined with capecitabine in metastatic HER2-negative breast cancer patients with brain metastases.

Trial Details

NCT ID
NCT05535413
Phase
PHASE1 / PHASE2
Sponsor
Hunan Cancer Hospital
Status
RECRUITING
Cancer Type
Breast Cancer
Interventions
  • UTD1 combined with capecitabine
Locations (sample)
  • Changsha, China|28.19874,112.97087

Key Eligibility Criteria

  • Patients aged 18 to 70 years
  • With histologically confirmed HER2 negative recurrent and metastatic breast cancer
  • have at least one measurable lesion in the central nervous system (the longest diameter ≥ 10mm)
  • ECOG score (PS) of 0-2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Breast Cancer Trials on Trialify →